Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Non-Small Cell Lung Cancer
Study Published in the Journal of Clinical Oncology REPORTS PHASE II efficacy and safety DATA of FIGITUMUMAB (CP-751,871) In patients with non-small cell lung cancer Results Support Ongoing Phase III AD
May 26th, 2009
Results Support Ongoing Phase III ADVIGO clinical trial program for figitumumab in NSCLC, including ADVIGO 1016 and 1018 A Phase II study of Pfizer's investigational anti-insulin growth factor type 1 receptor (IGF-1R) antibody, figitumumab (CP-751,871), met its primary endpoint of objective response rate (ORR) in patients with non-small cell lung cancer (NSCLC). Exploratory analyses of ORR and progression-free survival (PFS), a secondary endpoint, by dose and histology suggest a dose-response relationship in patients with differentiated histologies (squamous cell carcinoma and adenocarcinoma) but not in patients with undifferentiated, not otherwise specified (NOS)...
Source: Cancer Weekly (2009-05-26)
|
